PFW | Jotup

Marquez Valdes-Scantling, 2-Time Super Bowl Champion and Entrepreneur, Launches Runway Experience 'LUXE Fashion Fest'

Retrieved on:

Tuesday, April 9, 2024

Express, NLE Choppa, Super Bowl, MVS, Ice Spice, Collection, NYFW, PFW, Creativity, Kansas City Chiefs

On Friday, April 12, 2024, MVS will host a first-of-its-kind fashion experience called LUXE Fashion Fest.

Key Points:

On Friday, April 12, 2024, MVS will host a first-of-its-kind fashion experience called LUXE Fashion Fest.
Marquez Valdes-Scantling, 2-Time Super Bowl Champion and Entrepreneur, Launches Runway Experience 'LUXE Fashion Fest'
LUXE Fashion Fest will boast a formal runway show featuring both fresh and legacy faces in design, as well as sponsorship activations and a customized after party experience.
This year's LUXE Fashion Fest runway lineup highlights six dynamic designers from across the United States.
Legacy fashion brand, Express, is also delighted to partner with MVS on Luxe Fashion Fest as the presenting sponsor for this unique runway experience.

TransCode Therapeutics Reports Second Quarter 2023 Results; Provides Business Update

Retrieved on:

Monday, August 14, 2023

BOSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial results for the second quarter ended June 30, 2023, and recent business progress.

Key Points:

BOSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial results for the second quarter ended June 30, 2023, and recent business progress.
Research and development expense was $3.0 million in the second quarter of 2023, compared to $2.6 million in the second quarter of 2022.
General and administrative expense was $2.2 million in the second quarter of 2023, compared to $2.1 million in the second quarter of 2022.
TransCode expects that its cash of $3.6 million as of June 30, 2023, is sufficient to fund planned operations into September 2023 but not for a full 12 months from the date of its financial statements.

Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement

Retrieved on:

Saturday, December 3, 2022

VANCOUVER, British Columbia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”) is pleased to announce that, further to its news release on November 28, 2022, it has closed a non-brokered private placement of (i) 666,000 pre-funded warrants of the Company (“PFWs”) at a price of $1.249 per PFW (the “PFW Offering”), and (ii) 974,000 units of the Company (“Units”) at a price of $1.25 per Unit (the “Unit Offering”), for aggregate gross proceeds of $2,049,334.

Key Points:

Each Unit is comprised of one common share in the capital of the Company (a Share) and one common share purchase warrant (a Warrant).
Bright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain.
Bright Minds has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain.
Bright Minds drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Bright Minds Biosciences Announces Non-Brokered Private Placement

Retrieved on:

Monday, November 28, 2022

VANCOUVER, British Columbia, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”) is pleased to announce a non-brokered private placement of (i) pre-funded warrants of the Company (“PFWs”) at a price of $1.249 per PFW (the “PFW Offering”), and (ii) units of the Company (“Units”) at a price of $1.25 per Unit (the “Unit Offering”).The aggregate minimum gross proceeds of the Unit Offering and the PFW Offering, on a combined basis, is $1,000,000 (the “Minimum Offering”) and the aggregate maximum gross proceeds of the Unit Offering and the PFW Offering, on a combined basis, is $2,050,000. The Company, in its sole discretion, may determine the number of PFWs issued pursuant to the PFW Offering and the number of Units issued pursuant to the Unit Offering, provided that the aggregate proceeds raised is equal to or above the Minimum Offering amount.

Key Points:

The Unit Offering and the PFW Offering may close on one or more dates as the Company may determine.
Bright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain.
Bright Minds has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain.
Bright Minds drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.